Literature DB >> 27129551

Laparoscopic transfistulous bile duct exploration for Mirizzi syndrome type II: a simplified standardized technique.

Shu-Hung Chuang1,2, Meng-Ching Yeh1, Chien-Jen Chang3.   

Abstract

BACKGROUND: Laparoscopic treatment is a viable option for Mirizzi syndrome (MS) type I, but it is not recommended for MS type II (McSherry classification). We introduce laparoscopic transfistulous bile duct exploration (LTBDE) as a simplified standardized technique for MS type II.
METHODS: Eleven consecutive LTBDEs performed by a surgeon for MS type II were analyzed retrospectively, including three successful single-incision LTBDEs (SILTBDEs). Transfistulous stone removal followed by primary closure of gallbladder remnant and partial cholecystectomy was performed. An additional choledochotomy was required in one patient.
RESULTS: Preoperative endoscopic retrograde cholangiopancreatography and operative findings confirmed the diagnosis of MS in five and five patients, respectively. Preoperative ultrasound implied the remaining diagnosis. The operative time was 270.5 ± 65.5 min. The stone clearance rate was 100 %. The postoperative length of hospital stay was 5.1 ± 2.2 days. There was no open conversion. Overall complications comprised two postoperative transient hyperamylasemia (18.2 %) and one superficial wound infection (9.1 %). Compared with the other group of 92 patients who underwent laparoscopic bile duct exploration, the MS type II group had a significantly younger age, a higher jaundice rate, a lower single-incision laparoscopic approach rate, a lower choledochotomy rate, longer operative time, a lower postoperative pethidine dose, and a longer total length of hospital stay. The average follow-up period was 12.1 months.
CONCLUSIONS: LTBDE is safe and efficacious for MS type II including Csendes type IV. A high suspicion of MS is critical. SILTBDE is feasible in selected cases. Long-term follow-up is mandatory.

Entities:  

Keywords:  Choledochotomy; Cystocholedochal; Infundibulotomy; Laparoscopic bile duct exploration; Mirizzi syndrome; Single-incision laparoscopic surgery; Transfistulous

Mesh:

Year:  2016        PMID: 27129551     DOI: 10.1007/s00464-016-4911-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  31 in total

Review 1.  Mirizzi syndrome: history, present and future development.

Authors:  Eric C Lai; Wan Yee Lau
Journal:  ANZ J Surg       Date:  2006-04       Impact factor: 1.872

2.  Mirizzi's syndrome with a high CA19-9 level mimicking cholangiocarcinoma.

Authors:  C L Lin; C S Changchien; Y S Chen
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

3.  Successful endoscopic treatment for Mirizzi syndrome type II under direct peroral cholangioscopy using an ultraslim upper endoscope.

Authors:  Dong Choon Kim; Jong Ho Moon; Hyun Jong Choi; Moon Han Choi; Tae Hoon Lee; Sang-Woo Cha
Journal:  Endoscopy       Date:  2014-03-27       Impact factor: 10.093

4.  Laparoscopic treatment of Mirizzi syndrome.

Authors:  A Vezakis; D Davides; K Birbas; B J Ammori; M Larvin; M J McMahon
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2000-02       Impact factor: 1.719

5.  Mirizzi syndrome.

Authors:  E J Lubbers
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

6.  Benign obstruction of the common hepatic duct (Mirizzi syndrome): diagnosis and operative management.

Authors:  Jaques Waisberg; Adriano Corona; Isaac Walker de Abreu; José Francisco de Matos Farah; Renato Arioni Lupinacci; Fábio Schmidt Goffi
Journal:  Arq Gastroenterol       Date:  2005-06-22

7.  Single-incision vs three-incision laparoscopic cholecystectomy for complicated and uncomplicated acute cholecystitis.

Authors:  Shu-Hung Chuang; Pai-Hsi Chen; Chih-Ming Chang; Chih-Sheng Lin
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

8.  Incidence and management of Mirizzi syndrome during laparoscopic cholecystectomy.

Authors:  M Schäfer; R Schneiter; L Krähenbühl
Journal:  Surg Endosc       Date:  2003-05-13       Impact factor: 4.584

9.  Mirizzi syndrome: history, current knowledge and proposal of a simplified classification.

Authors:  Marcelo A Beltrán
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

10.  Single-incision laparoscopic common bile duct exploration with conventional instruments: an innovative technique and a comparative study.

Authors:  Shu-Hung Chuang; Pai-Hsi Chen; Chih-Ming Chang; Yung-Fa Tsai; Chih-Sheng Lin
Journal:  J Gastrointest Surg       Date:  2013-12-18       Impact factor: 3.452

View more
  6 in total

1.  Single-incision laparoscopic common bile duct exploration in 101 consecutive patients: choledochotomy, transcystic, and transfistulous approaches.

Authors:  Shu-Hung Chuang; Min-Chang Hung; Shih-Wei Huang; Dev-Aur Chou; Hurng-Sheng Wu
Journal:  Surg Endosc       Date:  2017-06-22       Impact factor: 4.584

2.  One-session laparoscopic management of Mirizzi syndrome: feasible and safe in specialist units.

Authors:  Ahmad H M Nassar; Mahmoud K Nassar; Ines C Gil; Hwei J Ng; Ahmad M Yehia
Journal:  Surg Endosc       Date:  2020-07-06       Impact factor: 4.584

Review 3.  Current trends in the management of Mirizzi Syndrome: A review of literature.

Authors:  Hang Chen; Ernest Amos Siwo; Megan Khu; Yu Tian
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

Review 4.  Single-incision laparoscopy surgery: a systematic review.

Authors:  Sasan Saeed Far; Sepide Miraj
Journal:  Electron Physician       Date:  2016-10-25

5.  Laparoscopic management of type II Mirizzi syndrome.

Authors:  Fátima Senra; Lalin Navaratne; Asunción Acosta; Alberto Martínez-Isla
Journal:  Surg Endosc       Date:  2020-03-05       Impact factor: 4.584

6.  Novel peroral cholangioscopy-directed lithotripsy using an ultraslim upper endoscope for refractory Mirizzi syndrome: A case report.

Authors:  Jian Li; Shao-Ju Guo; Jing-Chao Zhang; Hong-Yan Wang; Kai Li; Cheng-Shan Xu; Xue-Fang Wang
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.